People
Evan Diamond is a partner on our Intellectual Property, Patent, Trademark and Copyright Litigation team. Evan focuses his practice on patent litigation matters, with an emphasis on the pharmaceutical and biotechnology industries. In federal court trials, inter partes reviews before the Patent Trial and Appeal Board, and appeals before the Federal Circuit, he has substantial experience representing pharmaceutical and life sciences technology companies through trial victory or to favorable business resolutions for products with hundreds of millions or billions of dollars in annual sales.
Evan has been acknowledged by IAM Patent 1000 as one of the "World's Leading Patent Professionals," and has been recognized for the past five years as a “Top Ranked Intellectual Property Litigation Attorney” and a “Rising Star" by Super Lawyers. Evan speaks and writes extensively on new developments impacting life sciences patents and business concerns for the industry.
Evan brings to his practice a technical background in chemistry and biochemistry, having received an M.S. from the University of Pennsylvania prior to entering the legal field.
J.D., Harvard Law School, cum laude
B.A., University of Pennsylvania, summa cum laude, Phi Beta Kappa
M.S. in Biochemistry, University of Pennsylvania
New York
U.S. Court of Appeals for the Federal Circuit
Federal Circuit Bar Association
Member of the New York Intellectual Property Law Association, New Jersey Intellectual Property Law
PTAB Bar Association
January 6, 2022
Evan Diamond discusses the infringement law for skinny labels
In the first three Final Written Decisions for inter partes reviews in the Hatch-Waxman context, obtained rulings from the PTAB for client Galderma upholding all challenged claims on patents covering Oracea®, a multi-million dollar drug for the treatment of rosacea
Obtained preliminary injunction and then permanent injunction against launch of a generic version of Oracea®, which was upheld by the Federal Circuit on appeal
Obtained favorable claim construction in second-filer Hatch-Waxman litigation regarding Oracea®, resulting in withdrawal of Paragraph IV challenge before trial
See more
September 1, 2021
“Purple Book” Patent Listing Under Biological Product Patent Transparency Act: What Is Required, and What to Expect?
June 7, 2021
Update on the Proposed TRIPS Waiver at the WTO: Where is it Headed, and What to Expect?
January 6, 2022
Evan Diamond discusses the infringement law for skinny labels
In the first three Final Written Decisions for inter partes reviews in the Hatch-Waxman context, obtained rulings from the PTAB for client Galderma upholding all challenged claims on patents covering Oracea®, a multi-million dollar drug for the treatment of rosacea
Obtained preliminary injunction and then permanent injunction against launch of a generic version of Oracea®, which was upheld by the Federal Circuit on appeal
Obtained favorable claim construction in second-filer Hatch-Waxman litigation regarding Oracea®, resulting in withdrawal of Paragraph IV challenge before trial
See more
September 1, 2021
“Purple Book” Patent Listing Under Biological Product Patent Transparency Act: What Is Required, and What to Expect?
June 7, 2021
Update on the Proposed TRIPS Waiver at the WTO: Where is it Headed, and What to Expect?
January 6, 2022
Evan Diamond discusses the infringement law for skinny labels
J.D., Harvard Law School, cum laude
B.A., University of Pennsylvania, summa cum laude, Phi Beta Kappa
M.S. in Biochemistry, University of Pennsylvania
New York
U.S. Court of Appeals for the Federal Circuit
Federal Circuit Bar Association
Member of the New York Intellectual Property Law Association, New Jersey Intellectual Property Law
PTAB Bar Association